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XPatient selection clearly plays a key role in surgical treat-
ments. During the study period from 2005 to 2011, we con-
sidered ECMO for all patients who were active on our
institutional waiting list or who decompensated during the
lung transplant evaluation process. However, the recipient
age for patients with pretransplant ECMO was significantly
lower than in the control group (46  15 years vs 57  14
years), suggesting that there was selection bias where age
cutoff was lower for pretransplant ECMO consideration
than the standard age cutoff for lung transplantation. We
did not routinely consider ECMO use as a bridge to lung
transplant in acute respiratory distress syndromes. Care-
fully selected patients were considered for lung retransplan-
tation after severe allograft dysfunction, either chronic or
acute after the initial lung transplantation. In our center,
patients with other organ failure (eg, kidney and liver)
were denied for redo lung transplantation. Therefore,
when, for example, renal failure after ECMO developed
in patients, they were in general not considered for lung
transplantation.
The type of ECMO support used to bridge patients (VA
or VV) to lung transplantation did not show a significant
difference in overall survival, although the 1-year survival
seemed higher at 77% with VV ECMO versus 65% with
VA ECMO. At the University of Pittsburgh Medical Cen-
ter, patients who were placed on VA ECMO had cardiac
failure in addition to respiratory failure, whereas patients
on VV ECMO had only respiratory failure. Therefore, pa-
tients who required VA ECMO might be sicker than pa-
tients who required VV ECMO. In addition, arterial
cannulation, which is required for VA ECMO, can cause
more complications, such as leg ischemia, arterial embo-
lism (eg, stroke, ischemic gut), and bleeding complication
with more intense anticoagulation. To avoid leg ischemia,
we routinely inserted a distal perfusion cannula when
a femoral artery was used for arterial cannulation. For
VV ECMO, femoral vein to internal jugular vein was the
most common cannulation site in this study. However, we
and others have reported the use of a bicaval dual-lumen
catheter as a bridge to lung transplantation.10-12 The
potential advantage with this cannula is to allow patients
to ambulate while waiting for lung transplantation so that
muscular deconditioning can be avoided. In this study, 3
patients received a single dual-lumen catheter for VV
ECMO; however, they also required mechanical ventilation
for adequate oxygenation. The efficacy of this cannula and
VV versus VA ECMO needs to be clarified through further
experience.
Study Limitations
This single-center study is a small-scale, retrospective
analysis with a short follow-up period. As such, the findings
of this study are limited, and a prospective, multicenter
study would provide more definitive conclusions.1070 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
After the implementation of the LAS system in 2005,
ECMO as a bridge to lung transplantation is safe and effica-
cious to support patients until donor lungs become available.
ECMO provides excellent survival when it is used in care-
fully selected patients and when lung transplants are per-
formed by experienced surgeons, resulting in less blood loss.
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Dr Charles Hoopes (Lexington, Ky). Yoshi, let me start by
commending you and your former colleagues at the University
of Pittsburgh for your interest in a complex and difficult patient
group. I think you are correct that historically these patients
were not listed for transplant or, if they were listed, frequently
died on the ventilator secondary to a failure of mechanical
ventilation.
However, having said this and sharing with you a common ex-
perience and belief that there is in fact a role for mechanical circu-
latory support technologies in this patient group, it would also be
fair to say that ours is a minority view and it is worth at least notinggery c April 2013
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Xthe legitimacy of some of these well-founded criticisms that are
available in your own database.
As your retrospective study demonstrates, more than half of the
patients undergoing transplantation from an ECMO bridge re-
quired ongoing extracorporeal support for primary graft dysfunc-
tion, and there is generally little debate that early allograft
dysfunction is a predictor of early mortality and late allograft mor-
bidity. It is clearly a predictor of prolonged postoperative courses
as was demonstrated by your institutional study, where the average
was 46 days for the bridging group as opposed to 27 days for those
without a bridge, and it is fair to say that this is associated with
a significant increase in health care costs.
In addition, as you noted, 6 of the 24 patients undergoing trans-
plantation from ECMO received cadaveric lobar transplants
because of donor–recipient size mismatches and the understand-
able need to limit the time of support on ECMO. So for those of
us who may be cynics in the audience, it would be easy to view
ECMO bridging as an expensive technology deployed in high-
risk patients who subsequently receive high-risk allografts,
albeit—and our experience has been the same—with comparable
outcomes at 1 and 2 years.
However, putting the study in that context, let me ask you 1
question with basically 3 simple parts. First, from a philosophical
standpoint, do you think that ECMO should be deployed as salvage
in these patients awaiting transplantation, or should mechanical
circulatory support in lung transplantation follow the same para-
digm we currently follow in cardiac transplantation? In short,
shouldn’t ECMO take an unstable patient and create a lower-risk
patient capable of a lower-risk transplant? In relation to that com-
ment, if we are going to continue using ECMO bridging as salvage
therapy for medically refractory patients failing mechanical venti-
lation, should we not consider once again the use of regionaliza-
tion of donor organs rather than the traditional system of local
centers first so as to prioritize organs to unstable patients on
ECMO? And finally from a purely philosophical standpoint, do
you see ECMO bridging as an evolving standard of care or should
public health policy make this application of technology available
only at a limited number of experienced referral centers?
Again, congratulations on dealing with this complex patient
population, and I look forward to your comments.
Dr Toyoda. Let me comment on the frequency of postoperative
ECMO use. I must admit we had a lower threshold to keep the
ECMO going post-transplant because the patient was already can-
nulated. As you know, some centers use intraoperative ECMO to
perform lung transplants, and they routinely keep the ECMO post-
operatively. In this study, we were able to wean the ECMO early
postoperatively in 4 patients, so ECMO might not be necessary
for these 4 patients. Having said that, we still had approximately
30% to 40% of patients who required ECMO.
In terms of salvage, at the University of Pittsburgh we used
ECMO as salvage in this study. I think that is okay, because our
study shows a 74% 2-year survival rate for the patients who other-
wise would surely die then. We surgeons want to use our abilities
to save patients’ lives, so I think this is okay.
Regarding regionalization, I agree with you. For the sick pa-
tients, I think regionalization would be better than local center first
policy. So we should review our lung allocation strategy.The Journal of Thoracic and CarIn terms of centers, I am not so sure we should limit to certain
centers, because the surgeon’s experience is more important. Even
in this study, an experienced surgeon who had performed more
than 100 lung transplants had a better outcome in postoperative
ECMOuse and bleeding, and shorter warm ischemic time, hospital
stay, and survival. So I don’t think we should limit centers.
Dr Craig Smith (New York, NY). Dr Toyoda, I am looking for
ways to make these data look better. Have you compared the out-
comes in this group on ECMO with the patients in the other group
who required cardiopulmonary bypass for double lungs?
Dr Toyoda.We did not analyze that, but that is a good idea and
we will do it.
Dr R. Duane Davis (Durham, NC). Congratulations on an ex-
cellent series in obviously a difficult cohort of patients. I am going
to follow-up what Dr Hoopes has said. Shouldn’t we start thinking
about this as a way of improving the candidacy of a lung transplant
recipient, instead of just getting them to transplant, make them bet-
ter? You had a 45-day length of stay. One of the things that we have
seen is we got away from doing bedbound support with ECMO and
started focusing on ambulatory ECMO. Then they start actually
behaving like any other lung transplant recipient. The concept
that has actually come out of Germany in terms of going preferen-
tially to ECMO compared with ventilation and all the complica-
tions you buy with that type of strategy certainly seem to make
a better recipient and outcome.
I would also be cautious to say that this should be widespread to
any center. If you look at the UNOS data set and say what are the
outcomes on all-comers for ECMO, they still are not really in an
acceptable range.At single centers that have a focus on this, the out-
comes can be acceptable, but you cannot say that they are the same.
If you are trying to say the 74% in yours is exactly the same as your
all-comers, that is just a statistical fluke of a low number of patients.
Higher risk, you are going to have less good outcomes.
Dr Matthias Loebe (Houston, Tex). I have 2 quick questions.
Can you expand on how many patients were put on ECMO in
your institution who did not reach the point to be transplant candi-
dates and then did not undergo transplantation? In other words,
what is your selection from a patient on ECMO to undergo
transplantation?
Can you comment on the lung allocation strategies? You men-
tioned repeatedly the fact that a LAS at this point does not get
any extra points for being on mechanical support. The opposite is
true that if you are put on mechanical support, pulmonary pressure
goes down, or even if you are extubated, that will give you a certain
disadvantage in organ allocation, as you know. So do you have any
suggestions how to deal with this problem?
Dr Toyoda. During this time period we put an additional 7 pa-
tients on ECMO, but they did not reach lung transplantation. So,
the success bridge rate is approximately 77%. But of those 7 pa-
tients, our decision was wrong in probably 3, because patients
had multiorgan failure at the time of ECMO. So the real success
rate may be 86% or so.
In terms of lung allocation, once a patient is on ECMO, we
should consider that fraction of expired oxygen is 100% for
those patients. ECMO is providing 100% oxygenation. So even
if patients are extubated, we should probably give them a high
score.diovascular Surgery c Volume 145, Number 4 1071
